Cargando…
Intracoronary Reopro during Percutaneous Coronary Intervention in Acute and Stable Patient can Influence Stent Thrombosis Formation (IRPASST) Study
BACKGROUND: In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Most clinical trials have studied mainly intravenous administration. Intracoronary (IC) bolus application of abciximab causes very high...
Autores principales: | Balghith, Mohammed, Al-Ghamdi, Ali, Zain, El harif, Al-Saileek, Ahmed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752878/ https://www.ncbi.nlm.nih.gov/pubmed/23983910 http://dx.doi.org/10.4103/1995-705X.115498 |
Ejemplares similares
-
Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Xu, Xingli, et al.
Publicado: (2020) -
Intracoronary injection of nitroglycerine can prevent unnecessary percutaneous coronary intervention
por: Nasiri-Partovi, Amirhossein, et al.
Publicado: (2022) -
The Long-term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro(®)) Coated Stent in Patients with Coronary Artery Disease
por: Kim, Weon, et al.
Publicado: (2004) -
Editorial: Intracoronary Imaging Guidance for Percutaneous Coronary Interventions
por: Caiazzo, Gianluca, et al.
Publicado: (2022) -
Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study
por: Kretzschmar, Daniel, et al.
Publicado: (2012)